# EDGAR Filing Document

**Accession Number:** 0000898427
**File Stem:** 0001884552-23-000001
**Filing Date:** 2023-2
**Character Count:** 16337
**Document Hash:** f1bb5908a6c7e319a64ce3d1fae9d7e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001884552-23-000001.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001884552-23-000001

**CONFORMED SUBMISSION TYPE**: 5

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** AXA S.A.
- **CENTRAL INDEX KEY:** 0000898427
- **STANDARD INDUSTRIAL CLASSIFICATION:** LIFE INSURANCE [6311]
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 5
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39603
- **FILM NUMBER:** 23625561

**BUSINESS ADDRESS:**
- **STREET 1:** 25 AVENUE MATIGNON
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75008
- **BUSINESS PHONE:** 0033800434843

**MAIL ADDRESS:**
- **STREET 1:** 25 AVENUE MATIGNON
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75008

**FORMER NAME:**
- **FORMER CONFORMED NAME:** AXA
- **DATE OF NAME CHANGE:** 20000613

**FORMER NAME:**
- **FORMER CONFORMED NAME:** AXA UAP
- **DATE OF NAME CHANGE:** 19970904
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** AXA INVESTMENT MANAGERS UK Ltd
- **CENTRAL INDEX KEY:** 0001536140
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 5
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39603
- **FILM NUMBER:** 23625563

**BUSINESS ADDRESS:**
- **STREET 1:** 22 BISHOPGATE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** EC2M 3XJ
- **BUSINESS PHONE:** 00442070031000

**MAIL ADDRESS:**
- **STREET 1:** 22 BISHOPGATE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** EC2M 3XJ
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** AXA Investment Managers Paris
- **CENTRAL INDEX KEY:** 0001577619
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 5
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39603
- **FILM NUMBER:** 23625564

**BUSINESS ADDRESS:**
- **STREET 1:** 6 PLACE DE LA PYRAMIDE
- **CITY:** PUTEAUX
- **STATE:** I0
- **ZIP:** 92800
- **BUSINESS PHONE:** 33 1 44 45 67 72

**MAIL ADDRESS:**
- **STREET 1:** 6 PLACE DE LA PYRAMIDE
- **CITY:** PUTEAUX
- **STATE:** I0
- **ZIP:** 92800
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** AXA IM Prime Impact GP S.a.r.l
- **CENTRAL INDEX KEY:** 0001965500
- **STATE OF INCORPORATION:** N4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 5
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39603
- **FILM NUMBER:** 23625565

**BUSINESS ADDRESS:**
- **STREET 1:** 2-4, RUE EUGENE RUPPERT
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2453
- **BUSINESS PHONE:** 33 1 44 45 97 54

**MAIL ADDRESS:**
- **STREET 1:** 2-4, RUE EUGENE RUPPERT
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2453
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** AXA Investment Managers S.A.
- **CENTRAL INDEX KEY:** 0001826635
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 5
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39603
- **FILM NUMBER:** 23625562

**BUSINESS ADDRESS:**
- **STREET 1:** 6 PLACE DE LA PYRAMIDE
- **STREET 2:** TOUR MAJUNGA
- **CITY:** PUTEAUX
- **STATE:** I0
- **ZIP:** 92800
- **BUSINESS PHONE:** 0033144457000

**MAIL ADDRESS:**
- **STREET 1:** 6 PLACE DE LA PYRAMIDE
- **STREET 2:** TOUR MAJUNGA
- **CITY:** PUTEAUX
- **STATE:** I0
- **ZIP:** 92800
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** AXA IM Prime Impact Master Fund I SCA SICAV-RAIF
- **CENTRAL INDEX KEY:** 0001884552
- **STATE OF INCORPORATION:** N4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 5
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39603
- **FILM NUMBER:** 23625566

**BUSINESS ADDRESS:**
- **STREET 1:** 2-4 RUE EUGENE RUPPERT
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2453
- **BUSINESS PHONE:** 352 621 233 175

**MAIL ADDRESS:**
- **STREET 1:** 2-4 RUE EUGENE RUPPERT
- **CITY:** LUXEMBOURG
- **STATE:** N4
- **ZIP:** L-2453
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVELATION BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001810560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 843898466
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 650-800-3717

**MAIL ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Petra Acquisition Inc.
- **DATE OF NAME CHANGE:** 20200423

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>AXA IM Prime Impact Master Fund I SCA SICAV-RAIF<br><sub>(Last) (First) (Middle)</sub><br>2-4 RUE EUGENE RUPPERT<br><sub>(Street)</sub><br>LUXEMBOURG, N4 L-2453<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-12-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Former 10% Owner_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>REVELATION BIOSCIENCES, INC. [ REVB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>AXA IM Prime Impact GP S.a.r.l<br><sub>(Last) (First) (Middle)</sub><br>2-4, RUE EUGENE RUPPERT<br><sub>(Street)</sub><br>LUXEMBOURG, N4 L-2453<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-12-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Former 10% owner_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>REVELATION BIOSCIENCES, INC. [ REVB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>AXA Investment Managers Paris<br><sub>(Last) (First) (Middle)</sub><br>6 PLACE DE LA PYRAMIDE<br><sub>(Street)</sub><br>PUTEAUX, I0 92800<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-12-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Former 10% owner_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>REVELATION BIOSCIENCES, INC. [ REVB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>AXA INVESTMENT MANAGERS UK Ltd<br><sub>(Last) (First) (Middle)</sub><br>22 BISHOPGATE<br><sub>(Street)</sub><br>LONDON, X0 EC2M 3XJ<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-12-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Former 10% owner_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>REVELATION BIOSCIENCES, INC. [ REVB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>AXA Investment Managers S.A.<br><sub>(Last) (First) (Middle)</sub><br>6 PLACE DE LA PYRAMIDE<br>TOUR MAJUNGA<br><sub>(Street)</sub><br>PUTEAUX, I0 92800<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-12-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Former 10% owner_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>REVELATION BIOSCIENCES, INC. [ REVB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>AXA S.A.<br><sub>(Last) (First) (Middle)</sub><br>25 AVENUE MATIGNON<br><sub>(Street)</sub><br>PARIS, I0 75008<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-12-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_Former 10% owner_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>REVELATION BIOSCIENCES, INC. [ REVB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common stock | 2022-01-10<sup>(1)</sup> |  | J<sup>(1)</sup> |  | 1958984<sup>(1)</sup> | A | 0<sup>(1)</sup> | 1958984<sup>(1)</sup> | D<sup>(2)(3)(4)</sup> |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders ofpublicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement

(2) The following parties may be deemed to have the power to vote and direct the disposition of the shares of Common Stock owned by AXA IM Prime Impact Master Fund ISCA
SICAV-RAIF (the "Fund"):(a) the Fund owns the shares of Common Stock reported herein, (b) the general partner of the Fund, AXA IM Prime Impact GP S.a.r.l, has appointed
AXA Investment Managers Paris S.A. ("AIFM") as the alternative investment fund manager of the Fund to undertake all functions required of an external alternative investmentfund manager, (c) the Fund with the consent of AIFM and duly represented by its general partner, AXA IM Prime Impact GP S.a.r.l, has also entered into a delegated portfoliomanagement agreement with AIFM and AXA Investment Managers UK Ltd. ("AXA IM UK") in order to appoint AXA IM UK to act as the portfolio manager of the Fund, (d) AXA
Investment Managers S.A. is the sole shareholder of AIFM and AXA IM UK, and (e) AXA S.A. is the controlling shareholder of AXA IM SA.

(3) The reporting persons do not believe that they constitute a "group" within the meaning of Rule 13d-5 under the Securities Exchange Act of 1934, as amended, and they do notbelieve that they are otherwise required to attribute to each other the beneficial ownership of the securities reported herein held by them or by any persons or entities for whomor for which AIFM or AXA IM UK provides investment management services. Each of the reporting persons also disclaims beneficial ownership of these securities except to theextent of that person's pecuniary interest therein.

(4) On July 28, 2022, the issuer closed a public offering, and, as a result of the dilutive effect of the public offering, the reporting persons ceased to beneficially own more than
10% of the issuer's Common Stock outstanding as of the close of business on July 28, 2022.

**Signature:** /s/ Mirko Dietz Board Member, AXA IM Prime Impact GP S.a.r.l  
**Date:** 2023-02-14

**Signature:** /s/ Paul Guillaume Board Member, AXA IM Prime Impact GP S.a.r.l  
**Date:** 2023-02-14

**Signature:** /s/ Mirko Dietz Board Member, AXA IM Prime Impact GP S.a.r.l  
**Date:** 2023-02-14

**Signature:** /s/ Paul Guillaume Board Member, AXA IM Prime Impact GP S.a.r.l  
**Date:** 2023-02-14

**Signature:** /s/ Enguerran Six Chief Compliance officer, AXA Investment Managers Paris S.A  
**Date:** 2023-02-14

**Signature:** /s/ Terrance Turner Chief Compliance Officer, AXA Investment Managers UK Ltd  
**Date:** 2023-02-14

**Signature:** /s/ Anthony Gilsoul Attorney-in-fact AXA Investment Managers S.A  
**Date:** 2023-02-14

**Signature:** /s/ Anthony Gilsoul Attorney-in-fact AXA S.A  
**Date:** 2023-02-14

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**